Paid Clinical Trials in Philadelphia, Pennsylvania

Paid Clinical Trials and Focus Groups by Location

All Locations ... United States » ... Pennsylvania » ... Philadelphia

Asthma Exacerbation Study

Condition: Asthma
Interventions: Drug: Fluticasone Furoate/GW642444; Drug: Fluticasone furoate
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Condition: Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Interventions: Biological: Rituximab; Other: Placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified March 2010
Recurrent Low Back Pain:Linking Mechanisms to Outcomes

Condition: Low Back Pain, Mechanical
Intervention: Other: Core Stabilization
Sponsors: Drexel University; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified March 2010
Clinical Prediction Rule for Clinical Lumbar Instability

Condition: Low Back Pain, Mechanical
Intervention: Other: Core Stabilization
Sponsor: Drexel University
Recruiting - verified March 2010
Relapse-Prevention Study With F2695 SR in Patients With Major Depressive Disorder

Conditions: Depression; Major Depressive Disorder
Interventions: Drug: F2695 SR; Drug: Placebo
Sponsor: Forest Laboratories
Recruiting - verified March 2010
Peripartum Cardiomyopathy

Condition: Pregnant Women With Peripartum Cardiomyopathy
Intervention:
Sponsors: University of Pittsburgh; National Institutes of Health (NIH)
Recruiting - verified March 2010
Study of PENNVAX™-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants

Condition: HIV-1 Infection
Intervention: Biological: PENNVAX-B
Sponsor: VGX Pharmaceuticals, LLC
Not yet recruiting - verified March 2010
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicines.

Condition: Acute Gout
Interventions: Drug: ACZ885; Drug: Triamcinolone acetonide
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Alzheimer's Disease Neuroimaging Initiative Grand Opportunity

Conditions: Mild Cognitive Impairment; Alzheimer's Disease
Intervention:
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); National Institute on Aging (NIA); National Institutes of Health (NIH)
Not yet recruiting - verified March 2010
Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

Conditions: Ovarian; Breast; Prostate; Pancreatic; Advanced Tumours
Intervention: Drug: olaparib
Sponsor: AstraZeneca
Recruiting - verified March 2010
Cognition in Postoperative Total Hip Arthroplasty and Total Hip Resurfacing Patients

Condition: Cognition
Intervention:
Sponsor: Rothman Institute Orthopaedics
Recruiting - verified March 2010
Efficacy and Safety Study of Iontophoretic Application of Terbinafine Gel in Subjects With Onychomycosis

Condition: Distal Subungual Onychomycosis
Interventions: Drug: Terbinafine Hydrochloride; Other: Purified Water
Sponsor: Nitric BioTherapeutics, Inc
Not yet recruiting - verified March 2010
Study Evaluating a Novel Ibuprofen Formulation in Episodic Tension-type Headache

Condition: Pain
Interventions: Drug: Ibuprofen; Drug: Placebo
Sponsor: Wyeth
Recruiting - verified March 2010
Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery

Condition: Stage IIIA Non-small Cell Lung Cancer
Interventions: Radiation: proton beam radiation therapy; Drug: cisplatin; Drug: etoposide; Procedure: therapeutic conventional surgery
Sponsor: Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified February 2010
Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Day Before PicoPrep

Condition: Bowel Preparation
Interventions: Drug: PicoPrep; Drug: HalfLytely
Sponsor: Ferring Pharmaceuticals
Not yet recruiting - verified February 2010
Maternal Newborn Health Registry

Condition: Pregnancy Outcome Trends in Low-resource Geographic Areas
Intervention: Other: There is no intervention associated with this study.
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified December 2009
A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Condition: Depression
Interventions: Drug: Armodafinil; Drug: Armodafinil; Drug: Placebo
Sponsor: Cephalon
Recruiting - verified February 2010
Long Term Chamomile Therapy for Anxiety

Condition: Generalized Anxiety Disorder
Intervention: Dietary Supplement: Chamomile (Matricaria recutita)
Sponsor: National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified February 2010
A Dose-escalation Study in Subjects With Advanced Malignancies

Condition: Advanced Malignancies
Intervention: Drug: INCB028060
Sponsors: Incyte Corporation; Novartis Pharmaceuticals
Recruiting - verified February 2010
Correlating Outcomes With Biochemical Markers to Estimate Time-progression in Idiopathic Pulmonary Fibrosis (IPF)

Condition: Idiopathic Pulmonary Fibrosis
Intervention:
Sponsors: University of Michigan; National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health (info added by University of Michigan Data Coordinating Center)
Recruiting - verified November 2009
Sedation With Dexmedetomidine During Cardiac Catheterization

Condition: Pulmonary Hypertension
Intervention: Drug: Dexmedetomidine
Sponsor: Children's Hospital of Philadelphia
Not yet recruiting - verified February 2010
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: insulin glargine
Sponsor: Novo Nordisk
Recruiting - verified March 2010
A Study in Patients With Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Exenatide; Drug: LY2189265; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Simvastatin Therapy for Moderate and Severe COPD

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: simvastatin; Drug: Placebo
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2010
Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy

Condition: Infantile Hemangioma
Interventions: Drug: Propranolol; Drug: Placebo
Sponsor: Pierre Fabre Dermatology
Recruiting - verified March 2010
A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4

Condition: Hepatitis C, Chronic
Interventions: Drug: RO5024048; Drug: peginterferon alfa-2a [Pegasys]; Drug: Ribavirin [Copegus]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America

Condition: Sexual Dysfunctions, Psychological
Interventions: Drug: Flibanserin; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis

Conditions: Vaginosis, Bacterial; Vaginal Infection
Interventions: Drug: GW05; Drug: GW05; Drug: GW05; Drug: Metronidazole
Sponsor: Graceway Pharmaceuticals, LLC
Recruiting - verified March 2010
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza

Condition: Influenza
Interventions: Drug: Oseltamivir; Drug: Oseltamivir
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

Condition: Hypertriglyceridemia
Interventions: Drug: AMR101 (ethyl icosapentate); Drug: AMR101 (ethyl icosapentate); Drug: Placebo
Sponsor: Amarin Pharma Inc.
Recruiting - verified February 2010
Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation

Conditions: Pregnancy; Unexplained Infertility
Interventions: Drug: Letrozole (aromatase inhibitor); Drug: Clomiphene Citrate; Drug: Follicle Stimulating Hormone (gonadotropin)
Sponsors: Yale University; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Penn State University; University of Colorado, Denver; University of Michigan; University of Pennsylvania; University of Texas; University of Vermont; Wayne State University
Not yet recruiting - verified March 2010
To Assess the Long-term Safety, Efficacy and Tolerability of Inhaled Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Aclidinium bromide; Drug: Aclidinium bromide; Drug: Placebo
Sponsors: Forest Laboratories; Almirall, S.A.
Recruiting - verified February 2010
12 Week Safety Trial of Flibanserin in Depressed Women Taking a Selective Serotonin Reuptake Inhibitor or Norepinephrine Serotonin Reuptake Inhibitor With Decreased Sexual Desire and Distress

Conditions: Sexual Dysfunctions, Psychological; Depression
Interventions: Drug: flibanserin 2; Drug: placebo; Drug: flibanserin 1
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y

Condition: Painful Diabetic Neuropathy
Interventions: Drug: GRT3983Y; Drug: Placebo
Sponsor: Grünenthal GmbH
Recruiting - verified February 2010
A Study in Semagacestat for Alzheimer's Patients

Condition: Alzheimer's Disease
Intervention: Drug: Semagacestat
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension

Conditions: Type 2 Diabetes Mellitus; Cardiovascular Disease; Hypertension; Inadequate Glycaemic Control
Interventions: Drug: Dapagliflozin; Drug: Placebo
Sponsors: AstraZeneca; Bristol-Myers Squibb
Recruiting - verified March 2010
Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin

Condition: Hepatitis C Virus
Interventions: Drug: BMS-650032; Drug: BMS-650032; Drug: BMS-650032; Drug: BMS-650032; Drug: Peginterferon Alfa-2a; Drug: Peginterferon Alfa-2a; Drug: Ribavirin; Drug: Ribavirin
Sponsor: Bristol-Myers Squibb
Recruiting - verified December 2009
Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD)

Conditions: Muscular Dystrophy, Duchenne; Ambulatory Care
Intervention: Drug: Idebenone (CATENA®)
Sponsor: Santhera Pharmaceuticals
Recruiting - verified February 2010
Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.

Condition: Multiple Sclerosis
Intervention: Drug: Betaseron (Interferon beta-1b, BAY86-5046)
Sponsor: Bayer
Recruiting - verified March 2010
Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults

Condition: HIV Infections
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2009
Preservative-Free Tafluprost (MK2452) for Open-Angle Glaucoma/Ocular Hypertension

Conditions: Open-Angle Glaucoma; Ocular Hypertension
Interventions: Drug: Preservative-Free MK2452 (Tafluprost); Drug: Comparator: timolol
Sponsor: Merck
Recruiting - verified March 2010
Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM1)

Condition: Hepatitis C, Chronic
Interventions: Drug: Boceprevir (SCH 503034); Drug: erythropoietin; Biological: Peginterferon alfa-2b (SCH 54031); Drug: Ribavirin (SCH 18908)
Sponsor: Schering-Plough
Recruiting - verified March 2010
A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: taspoglutide; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified March 2010
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: FF/GW642444 Inhalation Powder; Drug: GW642444 Inhalation Powder
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Combivent Respimat; Drug: Combivent CFC-MDI; Drug: Atrovent HFA + Albuterol HFA
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By Chemotherapy With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery

Condition: Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: erlotinib hydrochloride; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

Condition: Chronic Hepatitis C
Interventions: Drug: BMS-790052; Drug: BMS-650032; Drug: pegylated-interferon-α; Drug: ribavirin
Sponsor: Bristol-Myers Squibb
Recruiting - verified December 2009
A Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Study in Men With Premature Ejaculation

Condition: Premature Ejaculation
Interventions: Drug: GSK557296; Drug: GSK557296; Drug: placebo
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy

Conditions: Excessive Daytime Sleepiness; Narcolepsy
Interventions: Drug: Placebo; Drug: PF-03654746
Sponsor: Pfizer
Recruiting - verified March 2010
Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

Condition: Onychomycosis
Interventions: Drug: IDP-108; Drug: Vehicle
Sponsor: Dow Pharmaceutical Sciences
Recruiting - verified March 2010
A Multi-center Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of R7103 Following Repeated Inhalation in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease

Condition: COPD
Intervention: Drug: R7103
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: mitomycin C; Drug: sorafenib tosylate; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma

Condition: Malignant Melanoma
Interventions: Drug: RO5185426; Drug: dacarbazine
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)

Conditions: Arthritis; Arthritis, Rheumatoid; Autoimmune Diseases
Interventions: Drug: golimumab; Drug: golimumab or placebo; Drug: golimumab or placebo
Sponsors: Centocor, Inc.; Schering-Plough
Recruiting - verified February 2010
THE IMPROVE TRIAL: Improving Pain Management and Outcomes With Various Strategies of Patient-Controlled Analgesia (PCA)

Condition: Sickle Cell Disease
Interventions: Other: High Demand / Low Infusion; Other: PCA Dosing Plan
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2010
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

Conditions: Lymphoma; Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure; Other: informational intervention
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)

Conditions: Graft-Versus-Host Disease; Immune System Disorders
Interventions: Drug: Mycophenolate Mofetil; Drug: Placebo
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Newtwork (BMT CTN)
Recruiting - verified March 2010
A Study of Duloxetine in Major Depressive Disorder (MDD) and Associated Painful Symptoms

Condition: Major Depressive Disorder
Interventions: Drug: Duloxetine; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)

Condition: Attention-Deficit/Hyperactivity Disorder
Interventions: Drug: extended-release guanfacine hydrochloride; Drug: placebo; Drug: extended-release guanfacine hydrochloride
Sponsor: Shire Pharmaceutical Development
Recruiting - verified March 2010
The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis

Condition: Psoriasis
Interventions: Drug: Etanercept ONLY; Drug: Methotrexate and Etanercept
Sponsors: Amgen; Immunex Corporation
Recruiting - verified March 2010
TAXUS Libertē Post Approval Study

Condition: Coronary Artery Disease
Interventions: Device: TAXUS Liberté Paclitaxel-Eluting Coronary Stent; Drug: prasugrel; Drug: placebo; Drug: aspirin
Sponsors: Boston Scientific Corporation; Eli Lilly and Company; Daiichi Sankyo Inc.
Recruiting - verified March 2010
Initial Treatment of Patients With Immune Thrombocytopenic Purpura

Condition: Immune Thrombocytopenic Purpura
Interventions: Drug: Dexamethasone USP Micronized; Drug: Prednisone
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2010
Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma

Condition: Cancer
Intervention: Drug: TL32711
Sponsor: TetraLogic Pharmaceuticals
Recruiting - verified February 2010
A Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception

Condition: Contraception
Interventions: Drug: LNG20; Drug: Mirena
Sponsor: Medicines360
Recruiting - verified February 2010
Safety and Tolerability of TAK-491 Plus Chlorthalidone Compared to Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Essential Hypertension

Condition: Essential Hypertension
Interventions: Drug: TAK-491 and chlorthalidone; Drug: Olmesartan medoxomil-hydrochlorothiazide
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified February 2010
6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes

Condition: Type 1 Diabetes Mellitus
Interventions: Drug: INSULIN GLARGINE (HOE901); Drug: Neutral Protamine Hagedorn (NPH) insulin
Sponsor: Sanofi-Aventis
Recruiting - verified February 2010
Dose Ranging Study of Celivarone With Amiodarone as Calibrator for the Prevention of Implantable Cardioverter Defibrillator (ICD) Interventions or Death

Condition: Arrhythmia Prophylaxis
Interventions: Drug: Celivarone (SSR149744); Drug: amiodarone; Drug: placebo
Sponsor: Sanofi-Aventis
Recruiting - verified February 2010
A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Diabetic Painful Neuropathy

Conditions: Pain; Diabetic Neuropathy, Painful
Interventions: Drug: Placebo; Drug: JNJ-42160443
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Adding Nitazoxanide to Treatment for People With Hepatitis C Virus and HIV Coinfection

Conditions: HIV Infections; Hepatitis C Virus
Interventions: Drug: Nitazoxanide (NTZ); Drug: Peginterferon alfa-2a (PEG-INF); Drug: Ribavirin (RBV)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified October 2009
Carboplatin and Paclitaxel Combined With Cetuximab and/or Cixutumumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: cetuximab; Biological: cixutumumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)

Condition: Acute Myeloid Leukemia
Intervention: Drug: Compound AC220
Sponsor: Ambit Biosciences Corporation
Recruiting - verified March 2010
A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds

Condition: Human Papillomavirus Infection
Interventions: Biological: V503; Biological: Comparator: Menactra™ (Concomitant); Biological: Comparator: Adacel™ (concomitant); Biological: Comparator: Menactra™ (Non-Concomitant); Biological: Comparator: Adacel™ (Non-concomitant)
Sponsor: Merck
Recruiting - verified March 2010
Telephone Support to Improve Adherence to Anti-HIV Medications

Condition: HIV Infections
Interventions: Behavioral: Enhanced nursing telephone support; Behavioral: Standard care
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified October 2009
Nexavar® Versus Placebo in Locally Advance RAI-Refractory Differentiated Thyroid Cancer

Condition: Thyroid Neoplasm
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006); Drug: Placebo
Sponsors: Bayer; Onyx Pharmaceuticals
Recruiting - verified March 2010
Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease

Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: Fluticasone propionate/salmeterol combination product; Drug: Salmeterol; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma

Conditions: Lymphoma; Nonneoplastic Condition
Interventions: Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2010
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

Conditions: Brain and Central Nervous System Tumors; Neurotoxicity
Interventions: Drug: temozolomide; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Children and Adolescents

Conditions: HIV Infections; HIV-1
Intervention: Drug: Etravirine
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy

Condition: Castration-Resistant Prostate Cancer
Interventions: Drug: MDV3100; Drug: Placebo
Sponsor: Medivation, Inc.
Recruiting - verified March 2010
A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia

Condition: Schizophrenia
Interventions: Drug: PF-03463275; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo; Drug: insulin glargine (HOE901)
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne

Condition: Severe Nodular Acne
Intervention: Drug: CIP-Isotretinoin and Isotretinoin
Sponsor: Cipher Pharmaceuticals Inc.
Recruiting - verified February 2010
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Pioglitazone

Condition: Diabetes Mellitus, Type II
Interventions: Drug: Placebo; Drug: Dutogliptin
Sponsors: Forest Laboratories; Phenomix
Recruiting - verified February 2010
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Conditions: Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Interventions: Drug: Alogliptin; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder

Condition: Attention Deficit Hyperactivity Disorder
Intervention: Drug: LY2216684
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)

Conditions: Pain; Neuralgia, Postherpetic; Neuralgia; Mononeuropathies
Interventions: Drug: JNJ-42160443; Drug: Placebo
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus

Condition: Systemic Lupus Erythematosus
Interventions: Drug: placebo; Drug: rontalizumab
Sponsor: Genentech
Recruiting - verified February 2010
A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza

Conditions: Cough; Sore Throat; Nasal Congestion; Headache; Fever; Seasonal Influenza
Interventions: Drug: Peramivir 600mg; Drug: Peramivir 10 mg
Sponsors: BioCryst Pharmaceuticals; Department of Health and Human Services
Recruiting - verified March 2010
A Study in Relapse Prevention of Treatment-resistant Depression

Condition: Treatment Resistant Depression
Interventions: Drug: Olanzapine and Fluoxetine combination; Drug: Fluoxetine
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza

Conditions: Seasonal Influenza; Cough; Sore Throat; Nasal Congestion; Myalgia; Headache; Fatigue
Interventions: Drug: Peramivir; Drug: Peramivir
Sponsors: BioCryst Pharmaceuticals; Department of Health and Human Services
Recruiting - verified March 2010
Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy

Condition: Parkinson's Disease
Interventions: Drug: nicotine; Other: placebo comparator
Sponsor: Neuraltus Pharmaceuticals, Inc.
Recruiting - verified March 2010
AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis

Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: warfarin; Drug: placebo
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); Duke University
Recruiting - verified February 2010
Study Comparing One Versus Two Cortisone Injections for Trigger Finger

Conditions: Stenosing Tenosynovitis; Trigger Finger
Interventions: Drug: One cortisone injection; Drug: Two cortisone Injections
Sponsor: Rothman Institute Orthopaedics
Recruiting - verified March 2010
Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors

Condition: Haemophilia A or B With Inhibitors
Interventions: Drug: activated recombinant human factor VII, long acting; Drug: activated recombinant human factor VII, long acting; Drug: activated recombinant human factor VII, long acting
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease

Condition: Gaucher Disease, Type 1
Intervention: Drug: velaglucerase alfa
Sponsor: Shire Human Genetic Therapies, Inc.
Available - verified March 2010
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Preventing Acute Chest Syndrome by Transfusion Feasibility Study

Conditions: Sickle Cell Disease; Secretory Phospholipase A2; sPLA2
Interventions: Biological: Single blood transfusion; Behavioral: Standard care
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2010
A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis

Condition: Sarcoidosis
Interventions: Drug: Placebo; Drug: golimumab; Drug: ustekinumab
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
The Genetics of Evoked Responses to Niacin and Endotoxemia: The GENE Study

Condition: Healthy Volunteers
Intervention: Drug: Immediate Release Niacin, Extended Release Niacin, Endotoxin
Sponsor: University of Pennsylvania
Recruiting - verified March 2010
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Conditions: Bladder Cancer; Prostate Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: placebo administration
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage III or Stage IVA Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin

Condition: Diabetes Mellitus, Type II
Interventions: Drug: Dutogliptin; Drug: Placebo
Sponsors: Forest Laboratories; Phenomix
Recruiting - verified February 2010
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: vincristine sulfate; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: liraglutide; Drug: placebo; Drug: liraglutide; Drug: placebo; Drug: liraglutide; Drug: placebo
Sponsor: Novo Nordisk
Recruiting - verified February 2010
Prospective, Multi-Center Clinical Outcomes Study Evaluating the chronOS Strip Combined With Bone Marrow Aspirate

Condition: Degenerative Disc Disease With or Without Stenosis
Intervention: Device: chronOS strip
Sponsor: Synthes Spine
Recruiting - verified March 2010
A Study of Vaniprevir (MK7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies

Condition: Chronic Hepatitis C Infection (HCV)
Interventions: Drug: vaniprevir (MK7009); Drug: Comparator: Pegylated Interferon (Peg-IFN); Drug: Comparator: Ribavirin (RBV)
Sponsor: Merck
Recruiting - verified March 2010
A Study of V503 in Preadolescents and Adolescents

Conditions: Cervical Cancer; Vulvar Cancer; Vaginal Cancer; Genital Lesions; PAP Test Abnormalities; HPV Infections
Intervention: Biological: V503
Sponsor: Merck
Recruiting - verified March 2010
Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma

Condition: Asthma
Interventions: Drug: QMF149 Twisthaler®; Drug: Mometasone Twisthaler®
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
A Study of LY2189102 in Patients With Type 2 Diabetes

Condition: Type 2 Diabetes
Interventions: Drug: LY2189102; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
PF-02341066 in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Conditions: Brain and Central Nervous System Tumors; Lymphoma; Neuroblastoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: MET tyrosine kinase inhibitor PF-02341066; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Clazosentan in Aneurysmal Subarachnoid Hemorrhage

Condition: Aneurysmal Subarachnoid Hemorrhage
Interventions: Drug: Clazosentan; Drug: Clazosentan; Drug: Placebo
Sponsor: Actelion
Recruiting - verified March 2010
AZD2066 Neuropathic Pain - Mechanical Hypersensitivity

Conditions: Neuropathic Pain; Mechanical Hypersensitivity
Interventions: Drug: AZD2066; Drug: Placebo
Sponsors: AstraZeneca; Quintiles
Recruiting - verified March 2010
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin; Drug: leuprolide acetate; Drug: triptorelin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

Condition: Macular Edema Secondary to Central Retinal Vein Occlusion
Interventions: Biological: VEGF Trap-Eye 2.0mg; Drug: Sham
Sponsors: Regeneron Pharmaceuticals; Bayer
Recruiting - verified February 2010
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

Conditions: Leukemia; Lymphoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: dexrazoxane hydrochloride; Drug: doxorubicin hydrochloride; Drug: obatoclax mesylate; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Condition: Attention Deficit Disorder With Hyperactivity
Interventions: Drug: Placebo; Drug: OROS MPH
Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified February 2010
Trial To Study The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures

Condition: Epilepsy
Interventions: Drug: Lacosamide; Drug: Lacosamide; Drug: Lacosamide
Sponsor: UCB, Inc.
Recruiting - verified February 2010
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: PF-02341066; Drug: Pemetrexed; Drug: Docetaxel
Sponsor: Pfizer
Recruiting - verified March 2010
Long Term Safety Study of Tanezumab in Chronic Low Back Pain

Condition: Low Back Pain
Interventions: Biological: Tanezumab 20 mg; Biological: Tanezumab 10 mg
Sponsor: Pfizer
Recruiting - verified March 2010
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Conditions: Chordoma; Desmoid Tumor; Sarcoma
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A

Condition: Herpes Zoster in Autologous Hematopoietic Stem Cell Transplantation Recipients
Interventions: Biological: Herpes Zoster Vaccine 1437173A; Biological: Placebo vaccine (saline)
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Ablation Versus Anti-Arrhythmic (AA) Drug Therapy for AF - Pivotal Trial

Conditions: Atrial Fibrillation; Arrhythmia; Stroke Prevention; Mortality
Interventions: Device: Left atrial ablation; Drug: Rate or Rhythm Control Therapy
Sponsors: Mayo Clinic; National Heart, Lung, and Blood Institute (NHLBI); Duke University; St. Jude Medical; Biosense Webster, Inc.
Recruiting - verified February 2010
Study Evaluating Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in ErbB-2 Positive Advanced Breast Cancer

Conditions: Advanced Breast Cancer; Breast Cancer
Interventions: Drug: Neratinib + Paclitaxel; Drug: Trastuzumab + Paclitaxel
Sponsor: Wyeth
Recruiting - verified March 2010
A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors

Condition: Advanced Non-hematologic Malignancies
Intervention: Drug: PF-04605412
Sponsor: Pfizer
Recruiting - verified March 2010
A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency

Condition: Overactive Bladder
Interventions: Drug: Fesoterodine; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
A Study of the Safety and Effectiveness of CNTO 328 When Added to Velcade-Melphalan-Prednisone in Patients With Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: 328 plus VMP (Part 1, Part 2-Arm A); Drug: VMP Alone (Part 2-Arm B)
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)

Condition: B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Interventions: Drug: Lenalidomide; Drug: Chlorambucil
Sponsor: Celgene Corporation
Recruiting - verified February 2010
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status

Condition: Colorectal Cancer
Intervention: Drug: olaparib
Sponsors: AstraZeneca; Aptium Oncology Gastrointestinal Cancer Consortium
Recruiting - verified February 2010
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Condition: Neuroblastoma
Interventions: Genetic: loss of heterozygosity analysis; Other: cytology specimen collection procedure; Procedure: biopsy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC

Condition: Hepatocellular Carcinoma
Interventions: Drug: Brivanib; Drug: Brivanib Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified November 2009
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer

Condition: Chemotherapy Induced Anemia
Interventions: Biological: Biological: ACE-011; Drug: Placebo
Sponsors: Acceleron Pharma, Inc.; Celgene Corporation
Recruiting - verified March 2010
A Study of IMC-A12 in Combination With Sorafenib in Patients With Advanced Cancer of the Liver

Condition: Hepatocellular Carcinoma
Interventions: Biological: IMC-A12; Drug: sorafenib
Sponsor: ImClone LLC
Recruiting - verified February 2010
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)

Conditions: Advanced Myelodysplastic Syndrome; Myelodysplastic Syndrome; Secondary Acute Myeloid Leukemia After MDS; Thrombocytopenia
Interventions: Drug: eltrombopag olamine; Other: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Collecting Tumor Samples From Patients With Gynecological Tumors

Condition: Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma

Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Sorafenib (Nexavar, BAY43-9006) + Erlotinib, Tarceva
Sponsors: Bayer; Onyx Pharmaceuticals; OSI Pharmaceuticals; Hoffmann-La Roche
Recruiting - verified March 2010
Effect of LY2062430 on the Progression of Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: LY2062430; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma

Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of Kidney Tumors in Young Patients

Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Procedure: computed tomography; Procedure: magnetic resonance imaging
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Biological Samples From Young Patients With Hodgkin's Lymphoma

Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Tissue Samples From Patients With Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Other: biologic sample preservation procedure; Procedure: biopsy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma

Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial

Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study

Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: ACT-064992 (macitentan); Drug: Placebo
Sponsor: Actelion
Recruiting - verified March 2010
Imatinib in Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Interventions: Drug: QTI571; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Changes in DNA After Radiation Therapy in Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Genetic: microarray analysis; Other: laboratory biomarker analysis
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Tissue From Young Patients With Cancer

Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Tumor Marker YKL-40 in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Intervention: Other: laboratory biomarker analysis
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Conditions: Leukemia; Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients

Conditions: HIV Infections; Acquired Immunodeficiency Syndrome
Interventions: Drug: ATV/rtv 400/100mg; Drug: 48 weeks ATV/rtv 300/100mg once daily + ETR 200mg twice daily; Drug: ATV/rtv 300/100mg; Drug: TDF 300mg
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs

Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: tocilizumab [RoActemra]; Drug: Nonbiologic DMARDs of investigator's choice
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke

Conditions: Acute Ischemic Stroke; Stroke; Brain Infarction
Interventions: Drug: Eptifibatide; Drug: rt-PA
Sponsors: University of Cincinnati; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified February 2010
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy

Conditions: Chronic Myeloproliferative Disorders; Kidney Cancer; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nonneoplastic Condition; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sunitinib malate; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: docetaxel; Drug: doxorubicin; Drug: cyclophosphamide; Drug: cyclophosphamide; Drug: pegfilgrastim
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); Genentech; US Oncology Research
Recruiting - verified March 2010
An Evaluation of a New Technique Utilizing a Biologic Glue and Tissue Patch to Seal the Cut Edge of the Pancreas Following Removal of the Tail of the Pancreas

Conditions: Pancreatic Fistula; Distal Pancreatectomy Complications; Falciform Patch Pancreatic Closure; Fibrin Glue Pancreatic Closure
Interventions: Procedure: Falciform patch and fibrin glue application; Procedure: standard pancreatic closure
Sponsor: Thomas Jefferson University
Recruiting - verified February 2010
Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma

Condition: Renal Cell Carcinoma
Interventions: Drug: RAD001; Drug: sunitinib
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Effects of Pregabalin (Lyrica) on Sleep Maintenance in Subjects With Fibromyalgia

Conditions: Fibromyalgia; Sleep Disorders
Interventions: Drug: Pregabalin; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: temozolomide; Other: placebo
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study Evaluating the Effects of Neratinib in Women With Early Stage Breast Cancer

Condition: Breast Cancer
Interventions: Drug: neratinib; Other: placebo
Sponsor: Wyeth
Recruiting - verified March 2010
A Study of Ixabepilone as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: Ixabepilone; Drug: Doxorubicin; Drug: Paclitaxel
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder

Condition: Depression
Interventions: Other: Placebo; Drug: orvepitant
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
A Trial of CM-AT in Children With Autism

Condition: Autism
Interventions: Drug: CM-AT; Drug: Placebo
Sponsor: Curemark
Recruiting - verified March 2010
ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

Conditions: Idiopathic Pulmonary Fibrosis; Pulmonary Hypertension
Intervention: Drug: Ambrisentan or placebo
Sponsor: Gilead Sciences
Recruiting - verified March 2010
Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)

Condition: Myocardial Infarction
Interventions: Drug: Prochymal®; Drug: Placebo
Sponsor: Osiris Therapeutics
Recruiting - verified March 2010
A Study of Tanezumab in Adults With Chronic Low Back Pain

Condition: Low Back Pain
Interventions: Biological: Tanezumab 20 mg IV; Drug: Placebo for naproxen; Biological: Tanezumab 10 mg IV; Drug: Placebo for naproxen; Biological: Tanezumab 5 mg IV; Drug: Placebo for naproxen; Biological: Placebo for tanezumab; Drug: Naproxen; Biological: Placebo for tanezumab; Drug: Placebo for naproxen
Sponsor: Pfizer
Recruiting - verified March 2010
A Randomized Controlled Trial of Mandatory Naps for Physicians in Training

Condition: Fatigue
Intervention: Behavioral: Mandatory Naps
Sponsors: Department of Veterans Affairs; University of Pennsylvania
Recruiting - verified February 2010
Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: tetomilast; Drug: placebo
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified March 2010
The Effect Of Acadesine On Reducing Cardiovascular and Cerebrovascular Adverse Events In Coronary Artery Bypass Graft (CABG) Surgery (Study P05633AM1)

Conditions: Coronary Artery Bypass; Myocardial Infarction; Ventricular Dysfunction, Left; Stroke; Cardiopulmonary Bypass
Interventions: Drug: Acadesine; Drug: Normal Saline
Sponsor: Schering-Plough
Recruiting - verified March 2010
A Noninvasive Test for Fetal RHD Genotype

Condition: Rhesus D Genotype
Intervention:
Sponsors: Sequenom, Inc.; NAFTNet
Recruiting - verified March 2010
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

Conditions: Breast Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Musculoskeletal Complications; Pain; Prostate Cancer; Urinary Complications
Intervention: Drug: zoledronic acid
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
PDE5 Inihibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

Condition: Anterior Ischemic Optic Neuropathy
Intervention: Drug: Diagnostic procedures
Sponsor: Bayer
Recruiting - verified March 2010
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)

Conditions: Bipolar; Depression
Interventions: Drug: lurasidone; Drug: lurasidone; Drug: Placebo
Sponsor: Dainippon Sumitomo Pharma America
Recruiting - verified February 2010
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)

Condition: Bipolar Depression
Interventions: Drug: lurasidone + (lithium or divalproex); Drug: Placebo + (lithium or divalproex)
Sponsor: Dainippon Sumitomo Pharma America
Recruiting - verified February 2010
Vorinostat, Isotretinoin, and Combination Chemotherapy in Treating Young Patients Who Have Undergone Surgery for Embryonal Tumors of the Central Nervous System

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: isotretinoin; Drug: thiotepa; Drug: vincristine sulfate; Drug: vorinostat; Genetic: fluorescence in situ hybridization; Genetic: microarray analysis; Genetic: polymorphism analysis; Genetic: protein expression analysis; Other: immunohistochemistry staining method; Procedure: adjuvant therapy
Sponsors: Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified July 2009
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: cytarabine; Drug: idarubicin; Drug: mercaptopurine; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: tretinoin; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs

Condition: Epilepsy With Simple or Complex Partial Onset Seizures
Interventions: Drug: Eslicarbazepine acetate; Drug: Eslicarbazepine acetate
Sponsor: Sepracor, Inc.
Recruiting - verified February 2010
ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients

Conditions: Actinic Keratoses; Skin Neoplasms
Interventions: Drug: Aminolevulinic Acid; Other: Vehicle
Sponsor: DUSA Pharmaceuticals, Inc.
Recruiting - verified March 2010
Chemotherapy or Observation in Treating Patients With Stage I Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine ditartrate; Procedure: standard follow-up care
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2010
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma

Condition: Malignant Melanoma
Interventions: Drug: ABI-007; Drug: Dacarbazine
Sponsors: Abraxis BioScience Inc.; University of Arizona
Recruiting - verified August 2009
First Line Hepato Cellular Carcinoma (HCC)

Condition: Hepato Cellular Carcinoma (HCC)
Interventions: Drug: Brivanib; Drug: Placebo; Drug: Sorafenib; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified November 2009
Anemia Treatment for Advanced NSCLC Patients Receiving Chemotherapy

Conditions: Non-small Cell Lung Cancer; Anemia; Cancer; Lung Cancer
Interventions: Drug: darbepoetin alfa 500 mcg Q3W; Drug: placebo
Sponsor: Amgen
Recruiting - verified March 2010
Florpiramine F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients

Condition: Parkinson's Disease
Intervention: Drug: florpiramine F 18
Sponsors: Avid Radiopharmaceuticals; National Institutes of Health (NIH)
Recruiting - verified February 2010
Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Subjects With Type 2 Diabetes Mellitus

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Alogliptin and metformin; Drug: Alogliptin and metformin; Drug: Glipizide and metformin
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)

Condition: Optic Neuritis
Interventions: Drug: Glatiramer Acetate (Copaxone); Drug: placebo
Sponsor: Teva Pharmaceutical Industries
Recruiting - verified February 2010
Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy

Conditions: Herpes Zoster; HIV Infections
Interventions: Biological: Zoster Vaccine Live; Biological: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Adult AIDS Clinical Trials Group; Merck
Recruiting - verified May 2009
A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With TMC114r (Ritonavir), and TMC125 (Etravirine) in HIV-1 Infected Pregnant Women

Conditions: HIV; HIV Infections; Pregnancy
Interventions: Drug: TMC114 (darunavir); Drug: TMC125 (etravirine); Drug: TMC114r (ritonavir)
Sponsors: Tibotec, Inc; Tibotec Therapeutics, a Division of Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified March 2010
Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals

Condition: Alzheimer's Disease
Intervention: Drug: florpiramine F 18
Sponsors: Avid Radiopharmaceuticals; American College of Radiology Imaging Network; General Electric
Recruiting - verified February 2010
A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension

Condition: Hypertension, Pulmonary
Interventions: Drug: PF-00489791; Drug: PF-00489791; Drug: PF-00489791; Drug: PF-00489791; Drug: PF-00489791; Drug: placebo; Drug: sildenafil
Sponsor: Pfizer
Recruiting - verified February 2010
An Observational Study of Fungal Biomarkers

Condition: Aspergillosis
Intervention: Other: No Intervention
Sponsor: Merck
Recruiting - verified March 2010
Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar Depression

Condition: Bipolar Depression
Interventions: Drug: cariprazine; Drug: cariprazine; Drug: placebo
Sponsors: Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified March 2010
A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: Placebo; Drug: fluoxetine; Drug: duloxetine; Drug: duloxetine
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer (NSCLC)
Interventions: Drug: Paclitaxel; Drug: Carboplatin; Drug: CT-322; Drug: Bevacizumab; Drug: Bevacizumab placebo (ie saline solution)
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Study on the Effect of External Magnetic Stimulation on Patients With Parkinson's Disease

Condition: Parkinson's Disease
Intervention:
Sponsors: Samueli Institute for Information Biology; Parkinson's Disease Research, Education, and Clinical Center, Philadelphia; Children's Hospital of Philadelphia
Recruiting - verified February 2010
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Conditions: Anemia; Leukemia; Myelodysplastic Syndromes
Interventions: Biological: epoetin alfa; Drug: lenalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of People With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab

Conditions: Colon Cancer; Rectal Cancer
Interventions: Biological: Cetuximab; Drug: Irinotecan; Biological: IMC-A12
Sponsors: ImClone LLC; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified February 2010
A Study to Test the Safety and Effectiveness of the Experimental Drug, CNTO 328, in Patients With Solid Tumors

Conditions: Ovarian Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Lung Neoplasms
Intervention: Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
A Safety Study of VIVITROL® Administered to Health Care Professionals

Condition: Opioid Dependency
Intervention: Drug: VIVITROL
Sponsor: Alkermes
Recruiting - verified February 2010
Efficacy and Safety of N8 in Haemophilia A Subjects

Condition: Haemophilia A
Interventions: Drug: recombinant factor VIII (N8); Procedure: Blood drawn for laboratory testing
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases

Condition: Brain Metastases
Interventions: Drug: Vorinostat; Radiation: Radiation Therapy
Sponsors: Thomas Jefferson University; Merck
Recruiting - verified March 2010
Phase III Acute Coronary Syndrome

Condition: Acute Coronary Syndrome
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Pfizer; Duke University
Recruiting - verified October 2009
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

Conditions: Adrenocortical Carcinoma; Kidney Cancer; Liver Cancer; Neuroblastoma; Retinoblastoma; Sarcoma
Interventions: Biological: cixutumumab; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Dapagliflozin; Drug: Placebo
Sponsors: Bristol-Myers Squibb; AstraZeneca
Recruiting - verified October 2009
Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies

Condition: Advanced Solid Tumors
Intervention: Biological: TAK-701
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
Continuing Access To AG- 013736 (A406) For Patients Previously Receiving AG 013736 In Clinical Trials

Condition: Solid Tumors
Intervention: Drug: AG-013736
Sponsor: Pfizer
Recruiting - verified March 2010
Atorvastatin Three Year Pediatric Study

Condition: Familial Hypercholesterolemia
Intervention: Drug: atorvastatin
Sponsor: Pfizer
Recruiting - verified March 2010
Understanding Patient's Knowledge and Use of Acetaminophen

Condition: Liver Failure
Interventions: Behavioral: Focus Groups; Behavioral: Personal Interviews
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified February 2010
GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: Hedgehog antagonist GDC-0449; Genetic: gene expression analysis; Genetic: in situ hybridization; Genetic: reverse transcriptase-polymerase chain reaction; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified January 2010
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer´s Disease

Condition: Alzheimer´s Disease
Interventions: Drug: Immune Globulin Intravenous (Human), 10% (IGIV, 10%); Drug: Immune Globulin Intravenous (Human), 10% (IGIV, 10%); Other: Placebo solution
Sponsors: Baxter Healthcare Corporation; Alzheimer's Disease Cooperative Study (ADCS)
Recruiting - verified March 2010
Study of MK0663/Etoricoxib in Postorthopedic Knee Replacement Surgery Pain

Condition: Postorthopedic Knee Replacement Surgery Pain
Interventions: Drug: etoricoxib; Drug: Comparator: ibuprofen; Drug: Comparator: placebo
Sponsor: Merck
Recruiting - verified March 2010
Safety and Efficacy of Tapentadol Immediate Release (IR) and Oxycodone Immediate Release (IR) for Treatment of Acute Post-op Pain Following Elective Arthroscopic Shoulder Surgery

Condition: Postoperative Pain
Interventions: Drug: Oxycodone IR; Drug: Tapentadol IR
Sponsors: Ortho-McNeil Janssen Scientific Affairs, LLC; Grünenthal GmbH
Recruiting - verified February 2010
Phase 2 Safety & Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 vs FOLFIRI in KRAS-mutant Metastatic Colorectal Carcinoma

Condition: Metastatic Colorectal Cancer
Interventions: Biological: AMG 479; Other: Placebo; Other: FOLFIRI; Biological: AMG 655
Sponsor: Amgen
Recruiting - verified March 2010
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

Conditions: Endometrial Cancer; Fatigue; Neurotoxicity
Interventions: Drug: carboplatin; Drug: paclitaxel; Radiation: brachytherapy; Radiation: intensity-modulated radiation therapy; Radiation: radiation therapy
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Comparative Study of Three NNRTI-Sparing HAART Regimens

Condition: HIV Infections
Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate; Drug: Raltegravir; Drug: Darunavir; Drug: Ritonavir
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Bristol-Myers Squibb; Gilead Sciences; Merck; Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
Recruiting - verified June 2009
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Pemetrexed; Drug: Pemetrexed; Drug: BIBF1120; Drug: Folic Acid; Drug: Folic Acid; Drug: BIBF1120 placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Study of Ataluren (PTC124™) in Cystic Fibrosis

Condition: Cystic Fibrosis
Interventions: Drug: Ataluren (PTC124); Drug: Placebo
Sponsors: PTC Therapeutics; Genzyme; Cystic Fibrosis Foundation
Recruiting - verified March 2010
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

Condition: Cervical Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US

Condition: Human Papillomavirus (HPV) Type 16/18 Infections and Cervical Neoplasia.
Intervention: Biological: GSK580299, GSK Biological's HPV vaccine
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor

Condition: Resected Stage III Melanoma With Macroscopic Involvement
Interventions: Drug: GSK 2132231A; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

Conditions: Atherosclerosis; Cardiovascular Disease; Coronary Heart Disease; CV Risk
Interventions: Drug: Darapladib; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
SR-PAAS - Sitaxentan Efficacy and Safety Trial With a Randomized Prospective Assessment of Adding Sildenafil

Conditions: PAH; Pulmonary Arterial Hypertension; Pulmonary Hypertension; Sitaxsentan; ETRA
Interventions: Drug: Sitaxsentan; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxentan Efficacy and Safety Trial With a Randomized Prospective Assessment of Adding Sildenafil

Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension; ETRA; PAH
Interventions: Drug: Sitaxsentan; Drug: Sitaxsentan and Sildenafil
Sponsor: Pfizer
Recruiting - verified March 2010
Open-label Study Providing Monotherapy (Sitaxsentan) and Combination Therapy (Sitaxsentan+Sildenafil) to Subjects With PAH to Assess Long-term Safety

Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension; PAH
Interventions: Drug: Sitaxsentan; Drug: Sitaxsentan and Sildenafil
Sponsor: Pfizer
Not yet recruiting - verified March 2010
Rollover Protocol for Prior SU011248 Protocols

Condition: Solid Tumors
Intervention: Drug: Sunitinib
Sponsor: Pfizer
Recruiting - verified March 2010
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Condition: Human Immunodeficiency Virus (HIV)
Intervention: Drug: Maraviroc
Sponsor: Pfizer
Recruiting - verified February 2010
Moderate to Severe Plaque Psoriasis With Scalp Involvement

Condition: Psoriasis
Interventions: Drug: etanercept / placebo; Drug: placebo / etanercept
Sponsor: Amgen
Recruiting - verified February 2010
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Welchol; Drug: placebo tablets
Sponsor: Daiichi Sankyo Inc.
Recruiting - verified March 2010
Phase III, Open-label Study of Nilotinib Versus Imatinib in GIST Patients

Condition: Gastrointestinal Stromal Tumor (GIST)
Interventions: Drug: Nilotinib (AMN107); Drug: imatinib (STI571)
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
PEAK: A Phase 2 Study of Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer Subjects With Wild-Type KRAS Tumors

Conditions: Colon Cancer; Colorectal Cancer; Rectal Cancer; Metastatic Colorectal Cancer
Interventions: Drug: Panitumumab; Drug: Bevacizumab; Drug: mFOLFOX6
Sponsor: Amgen
Recruiting - verified March 2010
A Study of MK0663/Etoricoxib for Post-Abdominal Hysterectomy Surgery Pain

Condition: Acute Pain Following a Total Abdominal Hysterectomy
Interventions: Drug: etoricoxib (MK0663); Drug: Comparator: Placebo
Sponsor: Merck
Recruiting - verified March 2010
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Condition: Pulmonary Fibrosis
Intervention: Drug: CNTO 888
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer

Condition: Advanced Breast Cancer
Interventions: Drug: Bosutinib; Drug: Exemestane
Sponsor: Wyeth
Recruiting - verified February 2010
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Psychosocial Effects of Cancer and Its Treatment; Sarcoma
Interventions: Other: educational intervention; Other: informational intervention; Other: internet-based intervention; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Other: survey administration; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment; Procedure: standard follow-up care
Sponsors: Tufts Medical Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study Evaluating Neratinib vs Lapatinib Plus Capecitabine for ErbB2 Positive Advanced Breast Cancer

Conditions: Advanced Breast Cancer; Breast Cancer
Interventions: Drug: Neratinib; Drug: Lapatinib plus Capecitabine
Sponsor: Wyeth
Recruiting - verified February 2010
Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass

Conditions: Pre-diabetes; Type 2 Diabetes
Interventions: Drug: Exenatide; Drug: Sitagliptin; Drug: Glimepiride
Sponsors: University of Pennsylvania; Pennsylvania Department of Health
Recruiting - verified March 2010
Panitumumab Combination Study With AMG 102 or AMG 479 in Wild-type KRAS mCRC

Conditions: Colon Cancer; Colorectal Cancer; Gastrointestinal Cancer; Metastatic Colorectal Cancer; Rectal Cancer
Interventions: Drug: Panitumumab + AMG 102; Drug: Panitumumab + AMG 479; Drug: AMG 479; Drug: AMG 102; Drug: Panitumumab
Sponsor: Amgen
Recruiting - verified March 2010
PKUDOS: PKU Demographic, Outcomes, and Safety Registry

Conditions: Phenylketonuria; Hyperphenylalaninaemia
Intervention: Drug: Sapropterin Dihydrochloride
Sponsor: BioMarin Pharmaceutical
Recruiting - verified January 2010
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib

Condition: Leukemia
Interventions: Drug: Dasatinib; Drug: Dasatinib
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2010
Safety Study of XL765 in Combination With Erlotinib in Adults With Solid Tumors

Conditions: Cancer; Non-small Cell Lung Cancer
Interventions: Drug: XL765; Drug: erlotinib
Sponsor: Exelixis
Recruiting - verified March 2010
Interleukin-2 Treatment for Wiskott-Aldrich Syndrome

Conditions: Wiskott-Aldrich Syndrome (WAS); X-linked Thrombocytopenia
Intervention: Drug: Interleukin-2
Sponsors: Children's Hospital of Philadelphia; Novartis
Recruiting - verified March 2010
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis

Conditions: Lupus Nephritis; Lupus Erythematosus, Systemic
Interventions: Drug: Abatacept; Drug: cyclophosphamide; Drug: azathioprine; Drug: prednisone; Drug: abatacept placebo; Drug: azathioprine placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network
Recruiting - verified February 2010
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Conditions: Deep Vein Thrombosis; Venous Thrombosis; Postphlebitic Syndrome; Venous Thromboembolism; Post Thrombotic Syndrome
Intervention: Drug: Recombinant tissue plasminogen activator (rt-PA)
Sponsors: Washington University School of Medicine; McMaster University; Ontario Clinical Oncology Group (OCOG); National Heart, Lung, and Blood Institute (NHLBI); Bacchus Vascular; BSN Medical Inc; Genentech; MEDRAD Interventional/Possis; Mid America Heart Institute; Society of Interventional Radiology Foundation; VasCore at Massachusetts General Hospital
Recruiting - verified February 2010
An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome

Condition: Carcinoid Syndrome
Interventions: Drug: lanreotide; Drug: placebo
Sponsors: Tercica; Ipsen
Recruiting - verified March 2010
Neuropsychological and Behavioral Testing in Young Patients With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor (PNET)

Conditions: Brain and Central Nervous System Tumors; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Therapy-related Toxicity
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
NINDS CRC Chronic Migraine Treatment Trial

Condition: Chronic Migraine
Interventions: Drug: propranolol LA; Drug: topiramate; Drug: placebo
Sponsors: The EMMES Corporation; National Institute of Neurological Disorders and Stroke (NINDS); Ortho-McNeil Janssen Scientific Affairs, LLC; CRC Operations Center
Recruiting - verified March 2010
(ARTEMIS-IPF)Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF

Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: ambrisentan or sugar pill
Sponsor: Gilead Sciences
Recruiting - verified March 2010
Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Exemestane + Dasatinib; Drug: Exemestane + Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohns Disease Who Have Been Previously Treated With Anti-TNF Therapy

Condition: Crohn's Disease
Intervention: Drug: Ustekinumab; CNTO1275
Sponsor: Centocor, Inc.
Recruiting - verified March 2010
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer

Conditions: Cancer; Carcinoma; Fallopian Tube Cancer; Gynecological Malignancies; Metastases; Oncology; Ovarian Cancer; Solid Tumors; Tumors
Interventions: Drug: Part 2, Cohort A: AMG 386 MTD Part 1 + Liposomal doxorubicin; Drug: B1: AMG 386 10 mg/kg + Topotecan; Drug: B2: AMG 386 3mg/kg + Topotecan; Drug: A1: AMG 386 10 mg/kg + Liposomal doxorubicin; Drug: A2: AMG 386 3mg/kg + Liposomal doxorubicin; Drug: Part 2, Cohort B: AMG 386 MTD part 1 + Topotecan
Sponsor: Amgen
Recruiting - verified March 2010
Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis

Condition: Scleroderma
Intervention: Drug: dasatinib
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2010
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION

Condition: Optic Neuropathy, Ischemic
Intervention:
Sponsor: Pfizer
Recruiting - verified March 2010
Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo

Condition: Alzheimer's Disease
Interventions: Drug: LY450139; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Transfusing Neonates Based on Platelet Mass

Condition: Thrombocytopenia
Intervention:
Sponsors: Christiana Care Health Services; Alfred I. duPont Hospital for Children; Thomas Jefferson University; Abington Memorial Hospital
Recruiting - verified March 2010
A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy

Condition: Soft Tissue Sarcoma
Intervention: Drug: PAZOPANIB
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Other: educational intervention
Sponsors: Fox Chase Cancer Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
A Placebo-Controlled Study of AZD0530 in Patients With Recurrent Osteosarcoma Localized to the Lung

Condition: Osteosarcoma
Interventions: Drug: AZD0530; Drug: Placebo
Sponsors: Sarcoma Alliance for Research through Collaboration; AstraZeneca
Recruiting - verified February 2010
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate to Severe Renal Insufficiency After the Administration of Magnevist

Conditions: Fibrosis; Kidney Failure; Renal Insufficiency
Intervention: Procedure: Lab sample drawn for serum chemistry at baseline visit
Sponsor: Bayer
Recruiting - verified March 2010
A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: ASA404 in combination with docetaxel; Drug: Placebo in combination with docetaxel
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Condition: Pancreatic Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder

Condition: Major Depressive Disorder (MDD)
Intervention: Drug: repeat dose
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Follow-Up Study for Exubera

Condition: Diabetes Mellitus
Interventions: Drug: Exubera; Other: Randomized diabetes therapy
Sponsor: Pfizer
Recruiting - verified March 2010
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Conditions: Brain and Central Nervous System Tumors; Cognitive/Functional Effects
Interventions: Drug: temozolomide; Drug: vorinostat; Procedure: adjuvant therapy; Procedure: cognitive assessment; Radiation: radiation therapy
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified January 2010
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Radiation: Radiation Therapy
Sponsors: Hoosier Oncology Group; Eli Lilly and Company
Recruiting - verified February 2010
Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"

Condition: Methicillin-Resistant S.Aureus
Interventions: Drug: Cephalexin; Drug: Clindamycin; Drug: Trimethoprim-sulfamethoxazole (TS); Drug: Placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2009
Study of CP-751,871 in Combination With Sunitinib in Patients With Advanced Solid Tumors

Conditions: Advanced Cancer; Advanced Solid Tumors
Interventions: Drug: CP-751,871; Drug: Sunitinib
Sponsor: Pfizer
Recruiting - verified March 2010
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Biological: bevacizumab; Drug: temsirolimus
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma

Condition: Locally Advanced and/or Metastatic Renal Cell Carcinoma
Interventions: Drug: Sunitinib; Drug: Pazopanib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Chemotherapy and Radiation Therapy With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Drug: cisplatin; Drug: vandetanib; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
TODAY Genetics Study

Condition: Type 2 Diabetes
Intervention:
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2010
An Extension Study of Tocilizumab in Patients Completing Treatment in Tocilizumab Core Studies

Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: Standard anti-rheumatic treatment
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: ifosfamide; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma

Condition: Relapsed Follicular Lymphoma
Interventions: Drug: VELCADE, rituximab, cyclophosphamide, prednisone, and Doxorubicin; Drug: VELCADE, rituximab, cyclophosphamide, and prednisone
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010
Safety and Efficacy Study of Daptomycin in Pediatric Subjects (2-17 Years)With Skin and Skin Structure Infections

Condition: Skin Diseases, Infectious
Interventions: Drug: Daptomycin; Drug: Vancomycin, Clindamycin or semi-synthetic Penicillins
Sponsor: Cubist Pharmaceuticals
Recruiting - verified February 2010
Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)

Condition: Huntington's Disease
Interventions: Drug: Creatine Monohydrate (HD-02); Drug: placebo
Sponsors: Massachusetts General Hospital; University of Rochester; National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified March 2010
A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas

Condition: Pancreatic Neoplasm
Interventions: Biological: monoclonal antibody; Drug: chemotherapy
Sponsors: Pfizer; University of Pennsylvania
Recruiting - verified March 2010
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Solar Melanoma That Cannot Be Removed By Surgery

Condition: Melanoma (Skin)
Intervention: Drug: dasatinib
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Efficacy Study of XL184 in Adults With Medullary Thyroid Cancer

Condition: Thyroid Cancer
Interventions: Drug: XL184; Drug: Placebo
Sponsor: Exelixis
Recruiting - verified March 2010
Randomized Sizing and Hemodynamic Study Mitroflow vs. Magna

Condition: Aortic Valve Disease
Interventions: Device: Mitroflow Aortic Pericardial Heart Valve (CarboMedics); Device: Carpentier-Edwards Magna Tissue Valve
Sponsor: Sorin Group USA, Inc.
Recruiting - verified March 2010
A Phase III Study of Alpharadin (Radium-223)in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases

Conditions: Hormone Refractory Prostate Cancer; Bone Metastases
Interventions: Drug: Alpharadin (Radium-223); Drug: Placebo
Sponsor: Algeta ASA
Recruiting - verified March 2009
A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Condition: Attention Deficit Hyperactivity Disorder
Interventions: Drug: atomoxetine hydrochloride; Drug: placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers

Condition: Retinoblastoma
Interventions: Genetic: DNA ploidy analysis; Genetic: DNA stability analysis; Genetic: Southern blotting; Genetic: genetic linkage analysis; Genetic: loss of heterozygosity analysis; Genetic: mutation analysis; Genetic: polymorphism analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: evaluation of cancer risk factors; Procedure: mutation carrier screening
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma

Condition: Solid Tumors and Lymphoma
Intervention: Drug: GSK1120212
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Chemotherapy and Radiation in Treating Patients With Stage 3 Non-Small Cell Lung Cancer

Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Etoposide; Drug: Cisplatin; Drug: Vinorelbine; Drug: Paclitaxel; Drug: Carboplatin; Radiation: Thoracic Radiation Therapy (TRT); Radiation: Thoracic Radiation Therapy (TRT)
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Phase II Trial of Silymarin for Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis

Condition: Non-cirrhotic Non-alcoholic Steatohepatitis
Interventions: Other: Placebo; Drug: Silymarin; Drug: Silymarin
Sponsors: Madaus Inc; University of Pennsylvania; University of North Carolina; Thomas Jefferson University; Beth Israel Deaconess Medical Center; University of Pittsburgh
Recruiting - verified December 2009
30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease

Conditions: Dyslipidemias; Coronary Heart Disease; Kidney Disease
Interventions: Drug: ABT-335; Drug: Rosuvastatin; Drug: Placebo
Sponsors: Abbott; AstraZeneca
Recruiting - verified February 2010
Safety Study of Denosumab in Subjects With Recurrent or Unresectable Giant Cell Tumor of Bone

Conditions: Cancer; GCT; Giant Cell Tumor of Bone
Intervention: Drug: Denosumab
Sponsor: Amgen
Recruiting - verified March 2010
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy

Condition: Brain and Central Nervous System Tumors
Intervention: Drug: cilengitide
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis

Condition: Multiple Sclerosis
Interventions: Drug: Teriflunomide (HMR1726); Drug: Placebo
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

Condition: Kidney Neoplasms
Interventions: Drug: Axitinib (AG-013736); Drug: Sorafenib
Sponsor: Pfizer
Recruiting - verified March 2010
Evaluating Dactinomycin and Vincristine in Young Patients With Cancer

Conditions: Kidney Cancer; Leukemia; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: dactinomycin; Drug: vincristine sulfate; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy

Conditions: Prevention of Venous Thromboembolism; Cancer
Interventions: Drug: AVE5026; Drug: Placebo
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
EZN-2285 or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: SC-PEG E. coli L-asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Prospective Observational Epidemiologic Study of Maraviroc's Safety

Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsor: Pfizer
Recruiting - verified March 2010
Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis

Condition: Bronchiectasis
Interventions: Drug: Inhaled mannitol; Drug: matched control
Sponsor: Pharmaxis
Recruiting - verified March 2010
TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents.

Condition: HIV-1
Intervention: Drug: TMC125
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: bortezomib; Drug: cytarabine; Drug: etoposide phosphate; Drug: idarubicin
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
CEP-701 (Lestaurtinib) in Myelofibrosis

Conditions: Myelofibrosis; Essential Thrombocythemia; Polycythemia Vera
Intervention: Drug: CEP-701 (Lestaurtinib)
Sponsor: Myeloproliferative Disorders-Research Consortium
Recruiting - verified February 2010
Research Tissue Bank

Conditions: Myelofibrosis; Idiopathic Myelofibrosis; Essential Thrombocythemia; Polycythemia Vera
Intervention:
Sponsor: Myeloproliferative Disorders-Research Consortium
Recruiting - verified February 2010
Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer

Condition: Adenocarcinoma of the Ovary
Intervention: Biological: OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine
Sponsor: AVAX Technologies
Recruiting - verified March 2010
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer

Condition: Esophageal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402

Conditions: Breast Cancer; Cognitive/Functional Effects; Fatigue; Psychosocial Effects of Cancer and Its Treatment; Sleep Disorders
Interventions: Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: fatigue assessment and management; Procedure: psychosocial assessment and care
Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Australian New Zealand Breast Cancer Trials Group; Cancer and Leukemia Group B
Recruiting - verified March 2010
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia

Condition: Euvolemic Hyponatremia
Interventions: Drug: lixivaptan; Drug: placebo
Sponsors: CardioKine Inc.; Cardiokine Biopharma, LLC; Biogen Idec
Recruiting - verified March 2010
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients

Condition: Kidney Transplantation
Interventions: Drug: Cyclosporine; Drug: CP-690,550; Drug: CP-690,550
Sponsor: Pfizer
Recruiting - verified March 2010
Dose-Intense Temozolomide in Recurrent Glioblastoma

Conditions: Glioblastoma; Gliosarcoma
Intervention: Drug: Temozolomide
Sponsors: Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital; University of Pennsylvania; Wake Forest University; Tufts Medical Center; Dartmouth-Hitchcock Medical Center; Schering-Plough
Recruiting - verified March 2010
A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome

Condition: Coronary Heart Disease
Interventions: Drug: dalcetrapib; Drug: Placebo; Drug: Evidence-based medical care for Acute Coronary Syndrome
Sponsor: Hoffmann-La Roche
Recruiting - verified March 2010
Dose Escalation and Remission (DEAR)

Condition: Ulcerative Colitis
Intervention: Drug: mesalamine
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Shire Pharmaceutical Development
Recruiting - verified February 2010
Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in People With Idiopathic Pulmonary Fibrosis

Condition: Pulmonary Fibrosis
Interventions: Drug: Prednisone; Drug: Azathioprine; Drug: N-acetylcysteine (NAC); Drug: Placebo
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2010
An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)

Condition: Chronic Angina
Intervention: Drug: Ranolazine
Sponsor: Gilead Sciences
Recruiting - verified February 2010
Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Condition: Venous Thrombosis
Interventions: Drug: Enoxaparin; Drug: warfarin; Drug: Placebo for apixaban; Drug: Placebo for enoxaparin; Drug: Placebo for warfarin; Drug: apixaban
Sponsors: Bristol-Myers Squibb; Pfizer
Recruiting - verified October 2009
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib; Drug: dexamethasone; Drug: lenalidomide
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting - verified March 2010
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Condition: Venous Thrombosis
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Pfizer
Recruiting - verified February 2010
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

Conditions: Advanced Non-Small Cell Lung Cancer; Transitional Cell Carcinoma; Soft Tissue Sarcoma; Gastric/Esophageal Adenocarcinoma; Pancreatic Cancer Including Ampulla of Vater
Interventions: Drug: brivanib; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146AM4)

Conditions: Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Large Cell; Carcinoma, Squamous Cell
Intervention: Drug: Temozolomide
Sponsor: Schering-Plough
Recruiting - verified March 2010
Defibrotide for Patients With Hepatic VOD: A Treatment IND Study

Condition: Hepatic Veno-Occlusive Disease
Intervention: Drug: Defibrotide
Sponsor: Gentium SpA
Recruiting - verified February 2010
Sorafenib Long Term Extension Program (STEP)

Condition: Neoplasms
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Sponsors: Bayer; ICON Clinical Research
Recruiting - verified March 2010
Transthyretin-Associated Amyloidoses Outcomes Survey (THAOS)

Condition: TTR-associated Amyloidosis
Intervention: Other: THAOS is a noninterventional patient registry
Sponsor: FoldRx Pharmaceuticals
Recruiting - verified February 2010
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Condition: Multiple Sclerosis
Interventions: Drug: Teriflunomide (HMR1726); Drug: Placebo
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients

Condition: Multiple Sclerosis
Interventions: Drug: CS-0777 tablets; Drug: CS-0777 tablets; Drug: CS-0777 tablets
Sponsor: Daiichi Sankyo Inc.
Recruiting - verified March 2010
Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Conditions: MDS; Myelodysplastic Syndromes; Thrombocytopenia
Interventions: Drug: Placebo; Biological: Romiplostim
Sponsor: Amgen
Recruiting - verified March 2010
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer

Condition: Small Cell Lung Cancer
Interventions: Drug: Cisplatin; Drug: Etoposide; Drug: Placebo; Drug: Cisplatin; Drug: Etoposide; Drug: ZD6474
Sponsors: Hoosier Oncology Group; AstraZeneca
Recruiting - verified February 2010
Aprotinin US Special Access Protocol

Condition: Postoperative Hemorrhage
Intervention: Drug: Trasylol (Aprotinin, BAYA0128)
Sponsor: Bayer
Available - verified March 2010
Examining the Genetic Factors That May Cause Chronic Obstructive Pulmonary Disease (COPD)

Conditions: Pulmonary Disease, Chronic Obstructive; Emphysema; Bronchitis, Chronic
Intervention:
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2009
Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Condition: Leukemia
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: lenalidomide
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group; Southwest Oncology Group
Recruiting - verified March 2010
A Phase III Trial of ZD4054 (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: ZD4054; Drug: Luteinising hormone-releasing hormone analogue (LHRHa); Drug: Megace; Drug: Estradiol; Drug: Prednisolone; Drug: Ketoconazole; Drug: Docetaxel
Sponsor: AstraZeneca
Recruiting - verified February 2010
Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock

Condition: Sepsis
Interventions: Drug: Drotrecogin alfa (activated); Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
PREGNANT Short Cervix Trial

Conditions: Preterm Delivery; Short Cervix; Short Uterine Cervical Length
Interventions: Drug: progesterone; Drug: placebo
Sponsors: Columbia Laboratories; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified March 2010
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Conditions: Crohn's Disease; Ulcerative Colitis; Inflammatory Bowel Diseases
Interventions: Biological: infliximab; Drug: conventional systemic agents; Biological: Biological therapies other than infliximab
Sponsor: Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified March 2010
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: lenalidomide; Drug: melphalan; Drug: prednisone; Drug: thalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women

Conditions: HIV Infections; Sexually Transmitted Diseases
Intervention: Biological: Quadrivalent human papillomavirus vaccine
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified June 2009
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bortezomib; Drug: carboplatin; Drug: dexamethasone; Drug: etoposide; Drug: ifosfamide; Genetic: polymerase chain reaction; Genetic: western blotting; Other: questionnaire administration
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia

Condition: Prostatic Hyperplasia
Interventions: Drug: Polyphenon E, 200 mg EGCG bid; Drug: placebo
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified February 2010
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising PSA After Surgery for Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Condition: Neuroendocrine Carcinoma
Interventions: Biological: bevacizumab; Biological: recombinant interferon alfa-2b; Drug: octreotide acetate
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer

Conditions: Esophageal Cancer; Adenocarcinoma of the Esophagus; Squamous Cell Carcinoma
Interventions: Drug: OncoGel (Paclitaxel gel); Drug: cisplatin; Drug: 5-FU; Radiation: radiation therapy; Procedure: esophageal resection
Sponsor: Protherics
Recruiting - verified March 2010
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis

Condition: Vascular Diseases
Interventions: Drug: Placebo + background low to moderate dose statin; Drug: BMS-582949 + Background low to moderate dose statin; Drug: Atorvastatin
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors

Conditions: Cognitive/Functional Effects; Metastatic Cancer; Neurotoxicity; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: memantine hydrochloride; Other: placebo; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: docetaxel; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Safety and Efficacy Study of the Sorin 3D Annuloplasty Ring For Mitral Repair

Condition: Mitral Valve Regurgitation
Intervention: Device: MEMO 3D Annuloplasty Ring for mitral valve repair
Sponsor: Sorin Group USA, Inc.
Recruiting - verified March 2010
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: PF-04494700; Drug: PF-04494700; Drug: Placebo
Sponsors: Pfizer; Alzheimer's Disease Cooperative Study (ADCS)
Recruiting - verified March 2010
Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in theTreatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen

Conditions: Colorectal Neoplasms; Neoplasm Metastasis
Interventions: Drug: Aflibercept (AVE0005); Drug: Placebo
Sponsors: Sanofi-Aventis; Regeneron Pharmaceuticals; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010
Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: lestaurtinib; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group
Recruiting - verified March 2010
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma

Condition: Retinoblastoma
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: thiotepa; Drug: vincristine sulfate; Procedure: autologous bone marrow transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia

Condition: Leukemia
Interventions: Biological: anti-thymocyte globulin; Drug: busulfan; Drug: cyclophosphamide; Drug: cyclosporine; Drug: methotrexate; Drug: methylprednisolone; Drug: tacrolimus; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: allogeneic bone marrow transplantation
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer

Condition: Prostate Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: samarium Sm 153 lexidronam pentasodium
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2010
Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: gemtuzumab ozogamicin; Drug: mercaptopurine; Drug: methotrexate; Drug: tretinoin
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia

Condition: Leukemia
Intervention: Drug: asparaginase-Erwinia
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
High-Dose or Standard-Dose Radiation Therapy and Chemotherapy in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Conditions: Lung Cancer; Radiation Toxicity
Interventions: Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel; Radiation: 3-dimensional conformal radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B
Recruiting - verified March 2010
A Study of Xeloda (Capecitabine) Plus Radiation Therapy in Children With Newly Diagnosed Gliomas

Condition: Glioma
Intervention: Drug: capecitabine [Xeloda]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis

Condition: Aspergillosis
Interventions: Drug: voriconazole; Drug: anidulafungin; Drug: voriconazole
Sponsors: Pfizer; Mycoses Study Group
Recruiting - verified February 2010
Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: docetaxel; Drug: flutamide; Drug: goserelin; Drug: leuprolide acetate; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Dialysis Catheter Comparative Clinical Trial

Condition: End Stage Renal Disease
Interventions: Device: Symmetric Tip Catheter; Device: Conventional Split-tip Catheter
Sponsor: Tyco Healthcare Group
Recruiting - verified March 2010
Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL® Wafer in Patients With Metastatic Brain Cancer

Condition: Metastatic Brain Cancer
Intervention: Drug: GLIADEL
Sponsor: Eisai Inc.
Recruiting - verified March 2010
Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures

Condition: Epilepsies, Partial
Interventions: Drug: pregabalin 600 mg/day; Drug: pregabalin 150 mg/day
Sponsor: Pfizer
Recruiting - verified March 2010
Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures

Condition: Epilepsy
Interventions: Drug: lacosamide; Drug: lacosamide
Sponsor: UCB, Inc.
Recruiting - verified March 2010
Study of Thymoglobulin to Arrest Newly Diagnosed Type 1 Diabetes

Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Antithymocyte globulin; Drug: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network
Recruiting - verified January 2010
Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients

Conditions: Gastrointestinal Cancer; Lung Cancer
Interventions: Drug: Melatonin; Drug: Placebo
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified February 2010
Randomized Phase 3b Study in Previously Untreated Multiple Myeloma Patients: VELCADE,Thalidomide, and Dexamethasone Versus VELCADE and Dexamethasone Versus VELCADE, Melphalan, and Prednisone

Condition: Multiple Myeloma
Interventions: Drug: bortezomib, thalidomide, and dexamethasone (VTD); Drug: bortezomib and dexamethasone (VD); Drug: bortezomib, melphalan and prednisone (VMP)
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010
Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Conditions: Psoriasis; Arthritis, Psoriatic
Interventions: Drug: conventional systemic agents; Biological: infliximab; Biological: ustekinumab; Biological: Biological therapies other than infliximab and ustekinumab
Sponsor: Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified March 2010
Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy

Condition: Epilepsy
Intervention: Drug: Levetiracetam
Sponsor: UCB, Inc.
Recruiting - verified February 2010
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy

Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Protocolized Care for Early Septic Shock

Conditions: Sepsis; Severe Sepsis; Septic Shock
Interventions: Procedure: Early Goal Directed Therapy (EGDT); Procedure: Protocolized Standard Care (PSC); Procedure: Usual Care (UC)
Sponsors: National Institute of General Medical Sciences (NIGMS); University of Pittsburgh
Recruiting - verified September 2008
Observation or Radical Treatment in Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Other: active surveillance; Procedure: conventional surgery; Procedure: quality-of-life assessment; Radiation: brachytherapy; Radiation: radiation therapy
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; Southwest Oncology Group
Recruiting - verified March 2010
Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: topotecan hydrochloride
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease

Condition: Moderate Risk of CVD
Interventions: Drug: Aspirin (Acetylsalicylic acid, BAYE4465); Drug: Placebo
Sponsor: Bayer
Recruiting - verified February 2010
Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis

Conditions: Candidiasis; Candida
Intervention: Drug: anidulafungin
Sponsor: Pfizer
Recruiting - verified March 2010
Compassionate Use Trial for Unresectable Melanoma With Ipilimumab

Condition: Melanoma
Intervention: Drug: Ipilimumab
Sponsor: Bristol-Myers Squibb
Available - verified March 2010
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Condition: Breast Cancer
Interventions: Biological: Trastuzumab; Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy

Condition: Breast Cancer
Interventions: Drug: Gemcitabine; Drug: Sorafenib; Drug: Placebo; Drug: Capecitabine
Sponsors: Accelerated Community Oncology Research Network; Onyx Pharmaceuticals
Recruiting - verified March 2010
Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotexate or Observation in Treating Patients With Acute Promyelocytic Leukemia

Condition: Leukemia
Interventions: Drug: mercaptopurine; Drug: methotrexate; Drug: tretinoin; Other: clinical observation
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Early Initiation of HAART

Condition: HIV Infections
Interventions: Procedure: Early Initiation of Highly Active Anti-Retroviral Therapy; Procedure: Standard Care
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH); International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Recruiting - verified February 2010
A Study of the Safety and Effectiveness of CNTO 148 (Golimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (CR014179)

Condition: Ulcerative Colitis
Interventions: Biological: golimumab, placebo; Biological: Golimumab, placebo; Biological: Placebo
Sponsors: Centocor, Inc.; Schering-Plough
Recruiting - verified February 2010
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

Condition: Invasive Breast Cancer
Interventions: Drug: doxorubicin; Drug: cyclophosphamide; Drug: paclitaxel; Drug: trastuzumab; Drug: lapatinib
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); GlaxoSmithKline
Recruiting - verified February 2010
Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Genetic: DNA ploidy analysis; Genetic: chromosomal translocation analysis; Genetic: fluorescence in situ hybridization; Genetic: polymorphism analysis; Other: immunologic technique; Other: laboratory biomarker analysis; Procedure: biopsy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients

Condition: Kidney Transplantation
Interventions: Drug: Cyclosporine; Drug: CP-690,550; Drug: CP-690,550
Sponsor: Pfizer
Recruiting - verified March 2010
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer

Condition: Tumor Antigen-positive Non-Small Cell Lung Cancer
Interventions: Biological: GSK1572932A Antigen-Specific Cancer Immunotherapeutic; Biological: Placebo Control
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOX

Condition: Cancer
Interventions: Drug: BMS-690514 / FOLFIRI; Drug: BMS-690514 / FOLFOX
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure

Condition: Heart Decompensation
Interventions: Drug: Placebo; Drug: Nesiritide
Sponsor: Scios, Inc.
Recruiting - verified February 2010
Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy

Condition: Pain, Postoperative
Interventions: Drug: pregabalin (Lyrica); Drug: pregabalin (Lyrica); Drug: matched placebo
Sponsor: Pfizer
Recruiting - verified March 2010
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox

Condition: Anemia
Intervention: Drug: Deferasirox
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)

Condition: Leukemia, Lymphocytic, Chronic
Intervention: Drug: alvocidib (HMR1275)
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
MONET1-MOtesanib NSCLC Efficacy and Tolerability Study

Condition: Non-small Cell Lung Cancer
Interventions: Drug: AMG 706; Drug: placebo
Sponsors: Amgen; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness

Conditions: Venous Thrombosis; Pulmonary Embolism
Interventions: Drug: Apixaban; Drug: Enoxaparin
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2010
PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response

Condition: Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck
Interventions: Drug: cisplatin + Docetaxel; Drug: Panitumumab
Sponsor: Amgen
Recruiting - verified March 2010
Efficacy of Proprietary Cherry Juice Blend in Osteoarthritis of the Knee

Condition: Osteoarthritis
Interventions: Other: proprietary cherry juice blend (food); Other: control juice (kool aid blend)
Sponsor: CherryPharm
Recruiting - verified March 2010
Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: cyclophosphamide; Drug: paclitaxel; Drug: pegylated liposomal doxorubicin hydrochloride; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B
Recruiting - verified March 2010
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia

Conditions: Cognitive/Functional Effects; Leukemia; Long-term Effects Secondary to Cancer Therapy in Children; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment
Interventions: Genetic: microarray analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: cognitive assessment; Procedure: diffusion tensor imaging; Procedure: management of therapy complications; Procedure: psychosocial assessment and care
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease

Conditions: Anemia; Chronic Kidney Disease; Kidney Disease
Interventions: Drug: darbepoetin alfa QW; Drug: darbepoetin alfa Q2W
Sponsor: Amgen
Recruiting - verified March 2010
Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft

Condition: Thoracic Aortic Aneurysms
Intervention: Device: Relay Thoracic Stent-Graft
Sponsor: Bolton Medical
Recruiting - verified March 2010
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Conditions: Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Neoplastic Syndrome
Interventions: Drug: motesanib diphosphate; Drug: octreotide acetate; Genetic: gene expression analysis; Genetic: protein expression analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: laboratory biomarker analysis; Procedure: computed tomography
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: docetaxel; Drug: goserelin; Drug: leuprolide acetate; Procedure: conventional surgery
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.

Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Sildenafil citrate; Drug: Sildenafil citrate; Drug: Sildenafil citrate; Drug: Sildenafil citrate
Sponsor: Pfizer
Recruiting - verified March 2010
Expanded Access Program for Maraviroc At Multiple Centers

Condition: HIV Infections
Intervention: Drug: maraviroc
Sponsor: Pfizer
Recruiting - verified February 2010
A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection

Condition: Hepatitis B, Chronic
Intervention: Drug: Entecavir
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial

Conditions: Cancer; Colon Cancer; Colorectal Cancer; Metastatic Cancer; Rectal Cancer; Metastatic Colorectal Cancer
Interventions: Drug: FOLFIRI - Panitumumab; Drug: FOLFIRI - Bevacizumab
Sponsor: Amgen
Recruiting - verified February 2010
Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

Conditions: Atrial Fibrillation; Atrial Flutter
Interventions: Drug: warfarin; Drug: apixaban
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)

Conditions: Vesico-Ureteral Reflux; Urinary Tract Infections
Interventions: Drug: Trimethoprim-Sulfamethoxazole; Drug: Placebo
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2010
Study of LYM-X-SORB™ to Improve Fatty Acid and Choline Status in Children With CF and PI

Conditions: Cystic Fibrosis; Pancreatic Insufficiency
Interventions: Dietary Supplement: Lym-X-Sorb powder; Dietary Supplement: Placebo powder
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2010
A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury

Conditions: Neuralgia; Spinal Cord Injuries
Interventions: Drug: placebo; Drug: pregabalin
Sponsor: Pfizer
Recruiting - verified March 2010
PROLIEVE® Post-Marketing Study TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)

Condition: Benign Prostatic Hyperplasia (BPH)
Intervention: Device: Prolieve® Thermodilatation System
Sponsor: Boston Scientific Corporation
Recruiting - verified February 2010
The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term Labor.

Condition: Premature Labor
Interventions: Drug: Placebo; Drug: GSK221149A
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
An Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis.

Condition: Interstitial Cystitis
Intervention: Drug: pentosan polysulfate sodium
Sponsor: McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Recruiting - verified February 2010
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma

Condition: Lymphoma
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Biological: rituximab; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: leucovorin calcium; Drug: liposomal cytarabine; Drug: methotrexate; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2010
Oseltamivir Treatment for Children Less Than 24 Months of Age With Influenza

Condition: Influenza
Intervention: Drug: oseltamivir (Tamiflu®)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2010
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Bevacizumab, Sorafenib, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer

Condition: Kidney Cancer
Interventions: Biological: bevacizumab; Drug: sorafenib tosylate; Drug: temsirolimus
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission

Conditions: Graft Versus Host Disease; Leukemia
Interventions: Drug: methotrexate; Drug: sirolimus; Drug: tacrolimus
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Treatment Decision Making Based on Blood Levels of Tumor Cells in Women With Metastatic Breast Cancer Receiving Chemotherapy

Condition: Breast Cancer
Intervention: Drug: chemotherapy
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS)

Condition: Osteoarthritis
Interventions: Drug: Celecoxib; Drug: Any commercially available NSAID with the indication for osteoarthritis
Sponsor: Pfizer
Recruiting - verified March 2010
A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.

Condition: Lupus Nephritis
Interventions: Drug: mycophenolate mofetil [CellCept]; Drug: Cyclophosphamide; Drug: mycophenolate mofetil [CellCept]; Drug: Azathioprine
Sponsors: Hoffmann-La Roche; Aspreva Pharmaceuticals
Recruiting - verified February 2010
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: gemtuzumab ozogamicin; Drug: mitoxantrone hydrochloride
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: clofarabine; Drug: cytarabine; Drug: methotrexate; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Drug: asparaginase; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: thioguanine
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection

Condition: Hepatitis B Infection
Intervention: Drug: Entecavir
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2010
Study to Evaluate Eye Function in Patients Taking Linezolid for Two Months or Greater

Condition: Optic Nerve Diseases
Intervention: Drug: Zyvox - linezolid
Sponsor: Pfizer
Recruiting - verified March 2010
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial

Conditions: Heart Failure; Anemia; Cardiovascular Disease; Ventricular Dysfunction; Congestive Heart Failure
Interventions: Drug: Darbepoetin alfa; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
VEGF Trap in Treating Patients With Metastatic or Unresectable Kidney Cancer

Condition: Kidney Cancer
Intervention: Biological: aflibercept
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: doxorubicin hydrochloride; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.

Condition: HIV-1
Intervention: Drug: TMC125
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen

Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; The Cleveland Clinic
Recruiting - verified March 2010
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma

Conditions: Childhood Malignant Fibrous Histiocytoma of Bone; Sarcoma
Interventions: Drug: doxorubicin hydrochloride; Drug: ifosfamide; Other: clinical observation; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Conditions: Leukemia; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Drug: sorafenib tosylate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma

Condition: Retinoblastoma
Interventions: Drug: carboplatin; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors

Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery

Condition: Kidney Cancer
Interventions: Drug: sorafenib tosylate; Drug: sunitinib malate; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; Southwest Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine ditartrate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group
Recruiting - verified March 2010
Cisplatin, Fluorouracil, Cetuximab, and Radiation Therapy in Treating Patients With HIV and Stage I, Stage II, or Stage III Anal Cancer

Condition: Anal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: fluorouracil; Radiation: radiation therapy
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2010
Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Procedure: adjuvant therapy; Procedure: conventional surgery; Procedure: neoadjuvant therapy; Radiation: radiation therapy
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study on the Effectiveness and Safety of Diazepam Injection (Vanquix™) for Patients With Epilepsy That Receive Antiepileptic Drugs, But Still Experience Acute Repetitive Seizures (Bouts or Clusters of Seizures) That Require Treatment

Conditions: Epilepsy; Epilepsy, Generalized; Epilepsy, Complex Partial; Epilepsies, Partial; Seizures
Interventions: Drug: Diazepam; Drug: Placebo
Sponsor: King Pharmaceuticals Research and Development
Recruiting - verified March 2010
Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer

Condition: Anal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: fluorouracil; Radiation: radiation therapy
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Azacitidine With or Without MS-275 in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Drug: azacitidine; Drug: entinostat
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: chemotherapy; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; American College of Surgeons; North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: antiandrogen therapy; Drug: docetaxel
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Condition: Adrenocortical Carcinoma
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: mitotane; Procedure: conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)

Condition: Pulmonary Hypertension
Interventions: Drug: bosentan; Drug: placebo
Sponsor: Actelion
Recruiting - verified March 2010
Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer

Condition: Prostate Cancer
Intervention: Device: Integrated Imaging High Intensity Focused Ultrasound
Sponsor: EDAP TMS S.A.
Recruiting - verified February 2010
Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease

Condition: Iron Overload
Intervention: Drug: deferiprone
Sponsors: Children's Hospital of Philadelphia; ApoPharma
Available - verified February 2010
Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer

Conditions: Head and Neck Cancer; Radiation Toxicity
Interventions: Drug: amifostine trihydrate; Drug: cisplatin; Drug: fluorouracil; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Southwest Oncology Group
Recruiting - verified March 2010
Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission

Condition: Leukemia
Interventions: Behavioral: compliance monitoring; Drug: mercaptopurine; Drug: methotrexate; Other: study of socioeconomic and demographic variables
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome

Condition: Turner Syndrome
Intervention: Drug: Somatropin
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

Condition: Bladder Cancer
Interventions: Biological: trastuzumab; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2010
Radiation Therapy in Treating Young Patients With Gliomas

Condition: Brain and Central Nervous System Tumors
Intervention: Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: clinical observation
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: CP-751,871 + paclitaxel + carboplatin; Drug: paclitaxel + carboplatin; Drug: CP-751,871 + paclitaxel + carboplatin; Drug: CP-751,871 + paclitaxel + carboplatin + erlotinib; Drug: CP-751,871 + paclitaxel + carboplatin + erlotinib
Sponsor: Pfizer
Recruiting - verified March 2010
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma

Condition: Sarcoma
Interventions: Biological: PEG-interferon alfa-2b; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified March 2010
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant

Conditions: Hepatitis C; Hepatitis C, Chronic
Interventions: Procedure: Continuous maintenance immunosuppressive therapy; Procedure: Immunosuppression withdrawal; Procedure: Liver transplant
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network
Recruiting - verified March 2010
Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy

Conditions: Metastatic Cancer; Prostate Cancer
Interventions: Drug: atrasentan hydrochloride; Drug: docetaxel; Drug: prednisone; Other: placebo
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia

Conditions: Leukemia; Lymphoma
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Biological: rituximab; Drug: cyclophosphamide; Drug: cytarabine; Drug: leucovorin calcium; Drug: methotrexate; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Drug: tacrolimus; Procedure: allogeneic bone marrow transplantation; Radiation: radiation therapy
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

Conditions: Brain and Central Nervous System Tumors; Carcinoma of Unknown Primary; Leukemia; Lymphoma; Metastatic Cancer; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Drug: topotecan hydrochloride
Sponsors: Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2008
Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: paclitaxel poliglumex; Other: clinical observation
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin's Disease

Condition: Lymphoma
Interventions: Drug: CHOP regimen; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: prednisone; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer

Condition: Breast Cancer
Intervention: Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Radiation Therapy Oncology Group; Southwest Oncology Group
Recruiting - verified March 2010
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Long-Term Effects of Treatment in Patients Previously Treated for Childhood Hodgkin's Lymphoma

Conditions: Long-term Effects Secondary to Cancer Therapy in Children; Lymphoma
Interventions: Other: medical chart review; Other: questionnaire administration; Procedure: management of therapy complications
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: lomustine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Nosocomial Pneumonia With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)

Condition: Pneumonia, Staphylococcal
Interventions: Drug: linezolid; Drug: vancomycin
Sponsor: Pfizer
Recruiting - verified February 2010
Study of Late-Occurring Complications in Childhood Cancer Survivors

Condition: Cancer
Interventions: Genetic: cytogenetic analysis; Genetic: mutation analysis; Genetic: polymorphism analysis; Other: questionnaire administration
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer

Condition: Breast Cancer
Intervention: Drug: exemestane
Sponsor: NCIC Clinical Trials Group
Recruiting - verified March 2010
Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: paclitaxel; Procedure: adjuvant therapy
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Zoledronate in Preventing Skeletal (Bone)-Related Events in Patients Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases

Conditions: Metastatic Cancer; Prostate Cancer
Interventions: Drug: zoledronic acid; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Southwest Oncology Group; Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Condition: Breast Cancer
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Biological: trastuzumab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer

Conditions: Breast Cancer; Menopausal Symptoms; Sexual Dysfunction and Infertility
Interventions: Drug: cyclophosphamide; Drug: goserelin
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; International Breast Cancer Study Group
Recruiting - verified March 2010
Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

Conditions: Brain and Central Nervous System Tumors; Lymphoma
Interventions: Biological: rituximab; Drug: methotrexate; Drug: temozolomide; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: tamoxifen citrate; Drug: triptorelin; Procedure: oophorectomy; Radiation: radiation therapy
Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Breast International Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group; National Surgical Adjuvant Breast and Bowel Project (NSABP); Southwest Oncology Group
Recruiting - verified March 2010
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Radiation: iodine I 125; Radiation: palladium Pd 103; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Emergency Use Program for HTE HIV+ Patients Who Need Tipranavir Treatment

Condition: HIV Infections
Intervention: Drug: Tipranavir
Sponsor: Boehringer Ingelheim Pharmaceuticals
Available - verified March 2010
Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: capecitabine; Drug: fluorouracil; Drug: oxaliplatin; Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors

Conditions: Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Ovarian Cancer
Interventions: Biological: bleomycin sulfate; Drug: cisplatin; Drug: etoposide; Procedure: conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Magnetic Resonance Imaging in Women Receiving Chemotherapy for Stage III Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: magnetic resonance imaging; Procedure: radiomammography; Procedure: spectroscopy; Radiation: gadopentetate dimeglumine
Sponsors: American College of Radiology Imaging Network; National Cancer Institute (NCI)
Recruiting - verified May 2007
Cyclophosphamide and Doxorubicin or Paclitaxel in Treating Women With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: therapeutic immune globulin; Other: clinical observation
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Isotretinoin With or Without Monoclonal Antibody, Interleukin-2, and Sargramostim Following Stem Cell Transplantation in Treating Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma

Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: busulfan; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: melphalan; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: University Hospitals, Leicester; National Cancer Institute (NCI); Children's Cancer and Leukaemia Group; Societe Francaise Oncologie Pediatrique; European Organization for Research and Treatment of Cancer; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria; Swiss Group for Clinical Cancer Research; EBMT Solid Tumors Working Party; Children's Oncology Group
Recruiting - verified March 2010
Paclitaxel in Treating Patients With Ovarian Stromal Cancer

Condition: Ovarian Cancer
Intervention: Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Long-Term Data Collection From Participants in Adult AIDS Clinical Trials

Condition: HIV Infections
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2009
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Condition: Melanoma (Skin)
Interventions: Biological: recombinant interferon alfa; Other: clinical observation
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; Children's Oncology Group
Recruiting - verified March 2010

Paid Clinical Trials in Philadelphia, Pennsylvania - Clinical Trials

Paid Clinical Trials in Philadelphia, Pennsylvania

Paid Clinical Trials and Focus Groups by Location

Main Menu

Find Clinical Trials

Clinical Trial Locations

Clinical Trial Categories

Patient Recruiting...

Paid Clinical Trials